Letter to Shareholders – 2025 a year of progress

AI SummaryClose X

Poolbeg Pharma plc reported significant progress in 2025, highlighted by an oversubscribed £4.865 million fundraise in June, extending its cash runway into 2027 with a £10.0 million cash balance as of June 30, 2025. The company is advancing its POLB 001 TOPICAL trial, which has secured teclistamab from Johnson & Johnson at no cost and is set to begin with interim data expected in summer 2026. Additionally, topline data for its oral GLP-1 program in obese subjects is anticipated in the first half of 2026, with the company actively pursuing partnering discussions for POLB 001, which addresses a potential market exceeding US$10 billion.

Disclaimer*

UK 100

Latest directors dealings